2 results match your criteria: "Research Centre of Portuguese Oncology Institute of Porto (GEBC CI-IPOP)[Affiliation]"
Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes.
Int J Mol Sci
May 2020
Cancer Biology and Epigenetics Group, Research Centre of Portuguese Oncology Institute of Porto (GEBC CI-IPOP), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
Oesophageal cancer is a life-threatening disease, accounting for high mortality rates. The poor prognosis of this malignancy is mostly due to late diagnosis and lack of effective therapies for advanced disease. Epigenetic alterations may constitute novel and attractive therapeutic targets, owing to their ubiquity in cancer and their reversible nature.
View Article and Find Full Text PDFA panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis.
Gastric Cancer
September 2020
IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), Rua Júlio Amaral de Carvalho, 45, 4200-135, Porto, Portugal.
Background: Gastric cancer is the fifth most common cancer and the third cause of global cancer mortality. CDX2 is an intestinal differentiation marker with prognostic value in gastric cancer and transcriptionally regulates the expression of glycoprotein A33 (GPA33) and liver intestine cadherin (LI-cadherin).
Methods: This study evaluated the clinical significance of the combined expression of CDX2 and its targets GPA33 and LI-cadherin in gastric cancer by fluorescence-based multiplex immunohistochemistry together with digital image analysis and chromogenic immunohistochemistry in 329 gastric cancer samples arranged in tissue microarrays.